Related Experiment Videos
Soluble CD30 in pediatric patients with atopic dermatitis
A Frezzolini1, M Paradisi, M Ruffelli
1Department of Immunodermatology, Istituto Dermopatico dell'Immacolata-IDI, IRCCS, Rome, Italy.
Allergy
|January 1, 1997
Summary
Soluble CD30 (sCD30) levels are elevated in children with atopic dermatitis (AD), correlating with disease severity. This suggests sCD30 is a valuable marker for assessing Th2 immune responses and disease activity in pediatric AD.
Area of Science:
- Immunology
- Dermatology
- Pediatrics
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition.
- T-helper 2 (Th2) cells are implicated in AD pathogenesis.
- Soluble CD30 (sCD30) is an activation marker for Th2-producing T-cell clones.
Purpose of the Study:
- To investigate serum sCD30 levels in pediatric AD patients.
- To correlate sCD30 levels with AD severity and other immune markers.
Main Methods:
- Serum samples were collected from pediatric AD patients (n=25), healthy donors (n=20), and urticaria patients (n=10).
- Disease severity was assessed using SCORAD and Costa et al. scoring systems.
- Serum sCD30 and soluble interleukin-2 receptor (sIL-2R) levels were measured.
Main Results:
- Serum sCD30 levels were significantly higher in AD patients compared to controls.
- A positive correlation was found between serum sCD30 and clinical AD severity scores.
- A significant association was observed between sCD30 and sIL-2R levels in AD patients.
Conclusions:
- Elevated sCD30 in pediatric AD confirms its role as an in vivo marker of Th2 immune response.
- sCD30 correlates with clinical disease activity and sIL-2R levels.
- sCD30 serves as an additional marker for evaluating disease activity in pediatric AD.